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Abstract
Objective
This study aimed at comparing the effect of a newly approved drug leveitiracetam 
(LEV) versus carbamazepine (CBZ) in the treatment of childhood focal epilepsy.
Materials & Methods  
The study population included newly diagnosed  children with focal epilepsy (1-16 
years old) referring to the Pediatric Neurology Ward of Quaem Hospital, Mashhad, 
Iran from May 2013 to March 2014. The subjects were randomly treated with LEV 
or CBZ. Patients were followed for seizure control and drug side effects throughout 
six months. We assessed liver function and complete blood count for all patients 
through one month and they were asked about significant side effects, such as 
drowsiness، restlessness, and skin reaction. Eventually, they were assigned in two 
groups (n=25) receiving LEV and CBZ.
Results
In our study, two cases in the LEV group were excluded because of severe agitation. 
Relapsing seizures were observed in 3 (13%) and 10 (40%) patients in LEV and 
CBZ groups, respectively. The seizure was not repeated in 15 cases (60%) in 
the CBZ group and 20 cases (87%) in the LEV group.  The results of the Chi-
squared test showed significant differences in the responses to treatment between 
the groups (P=0.03). Agitation was the most prevalent complication in the LEV 
group, whereas drowsiness was more common in the CBZ group. Fortunately, liver 
enzyme dysfunction and blood cell disturbances were not observed in the subjects.
Conclusion
According to the findings, there were significant differences in controlling seizures 
between two groups that indicated the effectiveness of LEV (87%) in the suppression 
of focal seizure.
Keywords: Childhood focal epilepsy; Carbamazepine; levetiracetam; Pediatric 
effectiveness.
70
Levetiracetam (levebel) Versus Carbamazepine Monotherapy for Focal Epilepsy in Children: A randomized clinical trial
Iran J Child Neurol. Spring  2020 Vol. 14 No. 2
Introduction
Epilepsy is a demanding neurological condition 
that affects many people worldwide. Selecting 
an appropriate antiepileptic drug (AED) is still 
challenging, because the selected drug should be 
effective, safe, and tolerable. Older generation of 
AEDs, such as phenobarbital and phenytoin are 
not widely accepted as a primary monotherapy and 
also long-term therapy for focal seizures, because 
of their side effects (1).
This problem is more common in pediatrics, 
particularly those over the age of one year. Only 
topiramate and oxcarbazepine are approved as 
monotherapy despite their side effects, such as 
leukopenia, aplastic anemia and drug-induced 
hepatitis. Because these drugs have the potential for 
drug interactions, reducing the serum level of other 
AEDs, and producing drug - drug  interaction, it is 
important to consider the safety and efficacy of an 
AED separately for monotherapy and adjunctive 
therapy(2).
The newer generation of AEDs have often more 
favorable side effects, including lesser somnolence 
and blood dyscrasia than the traditional AEDs. 
However, no comparative study has demonstrated 
the improved efficacy over carbamazepine (CBZ), 
phenytoin or valproic acid (3).
Levetiracetam (LEV), the S-enantiomer of alpha-
ethyl-2-oxo-1-pyrrolidine acetamide, is a novel 
AED that has been approved for use as an add-
on therapy for partial-onset seizures in children 
older than one year. In addition, LEV may provide 
effective seizure control when used as monotherapy 
(4). No serious toxicity has been reported for LEV 
(5). LEV does not affect the liver enzymes, like 
CYP450. Hence, there is no report on its major 
interaction with other AEDs (2).
Little evidence is available for LEV monotherapy 
in children younger than 16 years (6). Although 
several other studies have demonstrated successful 
conversion to monotherapy in a small number of 
children, the response rate with various durations 
of treatment in children with refractory epilepsy 
was as high as 66% (7,8).
To date, there are limited comparative findings 
regarding older and newer generations of AEDs 
(9) and there is no prospective study for this 
comparison.
This study aimed at comparing the effects of LEV 
and CBZ as monotherapy in children with focal 
seizures.
Materials & Methods
This Single-blind, randomized, prospective study 
(data recorder was blind to the drug administration) 
was conducted among 50 newly diagnosed  children 
having focal epilepsy and referring to the Quaem 
Hospital Pediatric Neurology Ward, Mashhad, Iran 
from May 2013 to March 2014. The age range of 
patients was 1-16 years. 
Research protocol was approved by the Ethics 
Committee of the Mashad University of Medical 
Sciences (t-3181) and the written informed consent 
was obtained from the parents of the subjects.
Patients
The age range of 1-16 years, newly diagnosed 
focal epilepsy, no history of refractory seizures, 
the lack of other systemic underlying disorders, 
especially renal, hepatic, or brain diseases, such 
as cerebral palsy and no history of previous AED 
use were the inclusion criteria. Those with pseudo- 
seizures, drug reaction and major side effects, 
such as Stevens-Johnson syndrome, drug-induced 
hepatitis, psychosis, renal disorders, severe 
agitation or any other minor problems, the lack 
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of parents’ willingness to participate in the study 
and clinical or electroencephalographic findings 
suggestive of idiopathic generalized epilepsy were 
the exclusion criteria. 
Study design. The study participants were 
randomly assigned to the two treatment groups 
receiving either LEV or CBZ. LEV (Levebel) 
was initiated at an initial dose of 10mg/kg/d and 
increased by 10mg/kg weekly until it reached the 
usual dose of 30mg/kg/d and continued. In the 
other group, CBZ (Loqman) was initiated at an 
initial dose of 5mg/kg/d and increased by 5 mg/
kg weekly until it reached the usual dose of 15mg/
kg/d and then continued.
At first, all participants were subjected to 
electroencephalography (EEG). To evaluate 
hepatic and hematologic side effects, complete 
blood count (CBC), alkaline phosphatase (ALKP) 
and aminotransferases (AST and ALT) tests were 
done one month later. Participants were assessed 
for side effects, such as somnolence, agitation, 
urticaria or skin itching. The patients then were 
divided into two 25-member groups, one group 
received LEV and the other one received CBZ. 
These groups were then sub-divided into two 
groups: responsive and non-responsive to therapy. 
Patients who completed the trial were considered to 
receive the allocated treatment until data analysis.
Statistics
Due to the lack of relevant study, this study was 
done as a pilot research. The subjects were initially 
dichotomized into two groups: those who treated 
with LEV and those with CBZ. The Student 
t-test and Chi-square test were used to compare 
continuous parametric and nonparametric data, 
respectively. The Fisher’s exact test was used 
for categorical variables. The seizure-free period 
was calculated for each subject. The occurrence 
of adverse events was compared between the two 
treatment groups using the dosage at the onset 
of the adverse events and the interval between 
the initiation of the AED administration and the 
occurrence of the adverse events. 
Results
The initial evaluation sowed 25 patients with 
seizures who were younger than 16 years treated 
with LEV and 25 cases treated with CBZ who met 
inclusion criteria. The demographic characteristics 
of the two treatment groups were comparable 
and all patients were followed for 6 months after 
the initiation of monotherapy (Table 1). Two 
participants receiving LEV were excluded from the 
study because they developed severe agitation. The 
final analysis was done on 48 participants. No other 
case was excluded to follow-up or discontinued 
taking the medication. There was no need to add 
adjunct AEDs during the follow-up period.
The mean age of the participants was 7.323± years 
in the CBZ group and 7.892.5± years in the LEV 
group. Based on the Independent sample t-test, 
there was no significant difference in terms of 
age between the groups (P value: 0.516). Twenty-
three participants (47.9%) had normal EEG (12 
participants in the CBZ group and 11 in the LEV 
group), whereas 25 participants (52.1%) had 
abnormal EEG (13 patients in the CBZ group and 
12 patients in the LEV group). Chi-square test 
revealed no significant difference in the frequency 
of participants with normal and abnormal EEG 
between the two groups (P value: 0.990). In the 
CBZ group, 10 participants (40%) (or 20.8% of the 
total participants) did not respond to the therapy 
and had one or more seizures during the follow-
up period. In the LEV group, only three (13%) 
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participants (6.3% of the total participants) did not 
respond to the therapy. Fifteen (60%) participants 
receiving CBZ and 20 participants (87%) receiving 
LEV responded to the therapy.
There was no significant difference between 
the participants who were free of seizure attacks 
during a six-month follow-up and those who had 
seizure attacks. Regardless of the seizure type, 
Chi-squared test revealed a statistically significant 
difference in the response to the therapy between 
the CBZ and LEV groups (P value: 0.035). 
The participants on LEV monotherapy had a 
significantly higher response rate. Moreover, in 
the LEV group, there was no significant difference 
between the participants who were free of seizure 
attacks through a six-month follow-up and those 
who were not.
In the CBZ monotherapy group, five participants 
(20%) had a complex partial seizure and 20 
subjects (80%) had secondary generalized seizures. 
Moreover, in the LEV monotherapy group, 5 
participants (21.7%) had complex partial seizures 
and 18 subjects (78.3%) had secondary generalized 
seizures during the follow-up period. Chi-square 
test revealed no statistically significant difference 
in the frequency and type of seizure between the 
two groups (P value: 0.882).
Totally, 16 subjects (32%) out of the 50 participants 
[9 (36%) on CBZ and 7 (28%) on the LEV] 
experienced at least one adverse event and none 
of the adverse events were life-threatening. Of the 
total participants, 68% subjects (34/50) did not 
show any adverse events [16 cases (64%) in the 
CBZ group and 18 cases (72%) in the LEV group]. 
in addition, the Chi-squared test revealed no 
statistically significant difference in the occurrence 
of complications between the two groups (P value 
0.853).
Six (12.5%) participants in the CBZ group reported 
somnolence and impaired consciousness; however, 
no somnolence sign was reported in the LEV group. 
The Chi-squared test results showed a statistically 
significant difference between the two groups (P 
value: 0.012).
There were no reported agitation signs in the CBZ 
group, whereas 7 cases (30.4% of the total) in the 
LEV group reported agitation signs. Considering 
those who were excluded, 7 out of the 25 
participants (36%) in the LEV group had agitation 
signs. The Chi-squared test results revealed a 
statistically significant difference in agitation signs 
between the two treatment groups (P value: 0.003).
On the other hand, dermatologic and hepatic 
complications were reported only in the CBZ 
group. However, there were no statistically 
significant differences in the occurrence of these 
side effects between the two groups.
Only one participant in the CBZ group developed 
a hepatic complication. Liver enzymes were three 
times more than the upper limit. The liver function 
test repeated one week later revealed that the level 
of the enzyme had returned back to the normal 
range, thus, the treatment was continued. No 
hepatic complication and skin reactions were seen 
or reported in the LEV group. Only two participants 
in the CBZ group developed skin complications 
(itching and redness) who were treated with anti-
histaminic medications. There was no hematologic 
complication among the participants in both groups. 
Furthermore, data analysis showed no statistically 
significant in all complications between the two 
groups.
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Table 1. Characteristics and adverse Event Profile of the patients receiving Levetiracetam and Carbamazepine
                                                              Levetiracetam            Carbamazepin             P-Value
Median age (year)                                     7.32±3                      7.89±2.5                       0.516                        
Gender                                                   56% (male)                60% (male)                      0.971
Epilepsy type
Complex partial seizure                          5 (21.7% )                    5 (20% )                       0.923
Secondary generalized seizure                18 (78.3% )                  20 ( 80% )                   0.882
Simple Partial                                                 0                                0                  
Response to therapy                                  20(87%)                      15(60%)                      0.035   
Complications
Agitation                                                   7(28%)                              0                             0.003
Somnolence                                                    0                             6(24%)                        0.012
Hematologic                                                   0                                 0  
Hepatic                                                           0                             1(4%)                           0.332
Dermatologic                                                  0                             2(8%)                          0.166
Discussion
It is difficult to design trials on the AED 
monotherapy  to demonstrate its use in clinical 
practices in children with focal seizure (10). LEV 
is a novel medication that has been approved by 
the Food and Drugs Administration (FDA) for 
adjunctive therapy in children older than one 
month with focal seizure (11).
Few studies have specifically examined LEV 
monotherapy in children with newly diagnosed 
focal epilepsy, whereas many studies have 
suggested the efficacy of LEV as add-on therapy 
in adults and children (4,6).
This was the first randomized clinical trial 
that compared the efficacy of LEV with CBZ 
monotherapy in children. In this study, we 
investigated the efficacy of LEV compared with 
CBZ regarding the newly diagnosed focal epilepsy. 
The main goal of the study was the elimination of 
the seizure for at least 6 months after treatment 
initiation and continuing the therapy with LEV 
or CBZ, which can indicate the efficacy of the 
medication. The standard formulation of the CBZ 
and LEV were used with a fixed starting dose, slow 
titration, and the possibility for patients to remain 
on the modest effective dose.
The primary outcome of this study was seizure 
remission for at least 6 months after the initiation 
of therapy with LEV or CBZ. More than 70% 
of the participants responded positively to these 
monotherapies and had no seizure through a six-
month follow-up, which is consistent with the 
results of Perry et al. (2008) study (11). Our results 
showed more effectiveness in participants receiving 
LEV with 87% reduction in seizure frequency 
than to those receiving CBZ (P value: 0.035). 
Seizure freedom may be a more reliable measure 
for a prospective review, as it is often more clearly 
documented in the chart and is less susceptible 
to the recall bias resulting from the reliance on 
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seizure-frequency counts provided by the parents. 
In the present study, all participants were subjected 
to monotherapy for at least six months. The 
majority of participants (87%) receiving LEV, 
(20/23 participants) experienced seizure freedom 
through a six-month follow-up. This proportion 
was significantly higher than the participants in the 
CBZ group (60%) who were seizure-free during the 
follow-up period. A previous study on 18 children 
treated with LEV did not report information about 
the conversion, treatment initiation, duration of 
treatment, and clinical response (12).
Another relevant study reported that 73% of the 
participants receiving LEV and 65% treated with 
CBZ were free of seizures. However, the proportion 
of those treated with CBZ who were free of seizures 
was slightly higher than our findings (11). Another 
study reported no statistically significant difference 
in seizures freedom between participants treated 
with LEV and CBZ (3). In contrast, our findings 
revealed a statistically significant difference in 
seizure remission between the participants in the 
LEV and CBZ groups (P value: 0.035). Other 
studies also reported a higher proportion of seizure-
free response among participants with partial 
seizure who received LEV monotherapy (8,9). 
Furthermore, 57% of the participants (children 
younger than 4 years) who were treated with LEV 
or CBZ monotherapy for focal seizures have been 
reported to be free of seizures during the first six 
months of follow-up (13).
We prescribed LEV at an initial dose of 10 mg/kg/d 
that was increased to 30 mg/kg/d and continued. 
Another study also suggested a lower dose of LEV 
(≤30 mg/kg/d). Ben-Menachem et al. reported that 
changing the LEV therapy from adjunctive therapy 
to monotherapy at a dose of 1500mg twice a day 
was effective in reducing or ceasing the seizures 
attack (15).
Studies on LEV monotherapy in adults and children 
have reported the effectiveness at relatively lower 
doses of LEV (12,13).
These studies also suggested LEV as an effective 
medication for seizure remission in childhood focal 
epilepsy. Among the patients treated with LEV 
(12,13,15), there were no significant differences 
in seizure type. Both CBZ and LEV were well 
tolerated as an initial monotherapy (12,13).
Only 30% of the participants receiving LEV and 
28% treated with CBZ had side effects. The findings 
showed no statistically significant difference in the 
occurrence of side effects in the studied groups. 
This may be due to the small sample size in our 
study. Besides, only two participants in the LEV 
group discontinued the monotherapy because of 
severe agitation. There were no other side effects 
leading to the discontinuation of therapy among the 
treatment groups. Similarly, another study reported 
that agitation was the most common side effect that 
caused treatment cessation (15).
In our study, all other side effects, such as hepatic 
dermatologic diseases and somnolence were 
only seen in those receiving CBZ. Somnolence 
was a more frequent complication in patients 
receiving CBZ that occurred at relatively normal 
daily doses. However, serum CBZ levels were 
not routinely available. As a result, we could 
not determine the effect of dosages on plasma 
concentrations in participants reporting these 
complications. Similarly, somnolence was the 
more frequent side effect among patients treated 
with CBZ (11). However, the side-effect profile 
of a particular formulation, such as the controlled-
release formulation of CBZ, which may be better 
tolerated, was not determined in this study. A 
statistically significant difference in agitation side 
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effect was also found between the two groups (P 
value: 0.012), which is consistent with the findings 
of other studies (16-20).
It is recommended to conduct more studies using 
a larger sample size to compare the presence of 
intolerable side effects more accurately between the 
two groups receiving the specified monotherapies. 
It can provide an appropriate finding regarding the 
effectiveness of a specific therapy more specifically 
. Our study indicated a significant difference 
in the effectiveness of the LEV as the first-line 
medication compared with the CBZ. This implies 
the noninferiority to CBZ and a more favorable 
effectiveness of the LEV as a monotherapy for 
focal seizures. However, data analysis showed no 
statistically significant difference between the two 
groups.
To select a treatment for a patient with newly 
diagnosed epilepsy, the side effects and long-term 
safety should be considered. LEV can probably 
be a proper substitution for CBZ  because it is 
associated with lower side effects, more safety, 
tolerability, and simpler pharmacokinetics that 
makes it a promising AED to be used as initial 
monotherapy in newly diagnosed epilepsy cases. 
The current study showed that children with newly 
diagnosed focal epilepsy treated with LEV had a 
better positive prognosis than those receiving CBZ. 
Strengths and Limitations
The use of seizures remission as an ultimate 
goal of treatment and as a marker of efficacy, the 
relative homogeneity between the groups, and 
using prospective design (randomized controlled 
trials) were the strengths of this study. However, 
this study was a pilot study using a small sample 
size. Hence, the direct comparison between the 
two groups with the antiepileptic monotherapies 
was limited. This study can provide strong findings 
for future trials on LEV monotherapy with a larger 
sample size in children younger than 16 years with 
focal epilepsy.
In conclusion
To select a treatment for a patient with newly 
diagnosed epilepsy, the side effects and long-term 
safety should be considered. LEV can probably 
be a proper substitution for CBZ  because it is 
associated with lower side effects, more safety, 
tolerability, and simpler pharmacokinetics that 
makes it a promising AED to be used as initial 
monotherapy in newly diagnosed epilepsy cases. 
The current study showed that children with newly 
diagnosed focal epilepsy treated with LEV had a 
better positive prognosis than those receiving CBZ. 
The use of seizures remission as an ultimate 
goal of treatment and as a marker of efficacy, the 
relative homogeneity between the groups, and 
using prospective design (randomized controlled 
trials) were the strengths of this study. However, 
this study was a pilot study using a small sample 
size. Hence, the direct comparison between the 
two groups with the antiepileptic monotherapies 
was limited. This study can provide strong findings 
for future trials on LEV monotherapy with a larger 
sample size in children younger than 16 years with 
focal epilepsy
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